Suppr超能文献

肝门部胆管癌切除术后近端胆管切缘状态的意义。

Significance of proximal ductal margin status after resection of hilar cholangiocarcinoma.

机构信息

Department of Subspecialty General Surgery, Mayo Clinic, Rochester, MN, 55905, USA.

Department of Transplant Surgery, Mayo Clinic, Jacksonville, FL, 32224, USA.

出版信息

HPB (Oxford). 2021 Jan;23(1):109-117. doi: 10.1016/j.hpb.2020.05.002. Epub 2020 Jun 25.

Abstract

BACKGROUND

The impact of additional resection for positive proximal bile duct margins during hepatic resection of hilar cholangiocarcinoma (HCCA) on survival and disease progression remains unclear. We asked how re-resection of positive proximal bile duct margins affected outcomes.

METHODS

Patients undergoing resection between 1993-2017 were reviewed. Both frozen section and final margin status were reviewed. Overall survival was the primary outcome.

RESULTS

153 patients underwent surgical resection for HCCA. Median survival (months) for initial margin negative (M-), margin-positive to margin-negative (M+/M-) and margin-positive to margin-positive (M+/M+) was 45, 33, and 35 months respectively. Nodal metastases increased with margin positivity: 32% with M-, 49% with M+/M- and 63% with M+/M+ (p = 0.016). Local/regional progression more frequently occurred in M+/M- (27.3%) and M+/M+ (33.3%) patients (M+/M- vs. M-: p = 0.41, M+/M+ vs. M-: p = 0.27). Patients receiving postoperative chemotherapy were 33% M-, 46% M+/M- and 63% in M+/M+. Postoperative radiation was used in 13% of M-, 31% of M+/M- and 63% of M+/M+. Most frequent initial recurrences were within the liver and hepaticojejunostomy site.

CONCLUSION

Competing risk for systemic disease based on primary characteristics of HCCA outweighs the impact of re-resection to achieve R0 status. Improved survival will likely depend on future regional and systemic therapy.

摘要

背景

在肝门部胆管癌(HCCA)的肝切除术中,对于阳性近端胆管切缘进行额外切除对生存和疾病进展的影响仍不清楚。我们询问了再次切除阳性近端胆管切缘如何影响结果。

方法

回顾了 1993 年至 2017 年间接受手术切除的患者。回顾了冰冻切片和最终切缘状态。总生存期是主要观察结果。

结果

153 例患者接受了 HCCA 的手术切除。初始切缘阴性(M-)、切缘阳性至切缘阴性(M+/M-)和切缘阳性至切缘阳性(M+/M+)的中位生存时间(月)分别为 45、33 和 35 个月。随着切缘阳性,淋巴结转移率增加:M-为 32%,M+/M-为 49%,M+/M+为 63%(p=0.016)。M+/M-(27.3%)和 M+/M+(33.3%)患者更常发生局部/区域进展(M+/M-与 M-相比:p=0.41,M+/M+与 M-相比:p=0.27)。接受术后化疗的患者中,M-为 33%,M+/M-为 46%,M+/M+为 63%。术后放疗用于 13%的 M-,31%的 M+/M-和 63%的 M+/M+。最初最常见的复发部位是肝脏和胆肠吻合口。

结论

基于 HCCA 的主要特征,全身性疾病的竞争风险超过了实现 R0 状态的再次切除的影响。改善生存可能取决于未来的区域和系统治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验